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The aim of this paper is to review the thrombogram and its use for phenotyping the
haemostatic system. The thrombogram can be readily obtained through Calibrated
Automated Thrombography (CAT), using a commercially available fluorometer,
dedicated software (ThrombinoscopeR) and a calibrator. Here we explore the
possibility to use platelet-rich plasma (PRP) triggered with a low amount of
recombinant human tissue factor (f 0.5 pM) and also explore the function of the
protein C system by adding activated protein C (APC) or soluble recombinant
thrombomodulin (TM). Examples are shown: inherited antithrombin (AT) and protein
C deficiencies, and antiphospholipid antibodies.
A 2004 Elsevier Ltd. All rights reserved.Introduction
Evidence has accumulated over years that tradi-
tional clotting assays, while quite informative for
marked haemostatic defects, fail to indicate in-4 Elsevier Ltd. All rights reserv
-83-68-34-70; fax: +33-3-
t@nancy.inserm.frcreased coagulability of patients suffering from
thrombosis. A striking example of this failure is
seen in patients with lupus anticoagulants (LA)
where the anticoagulant activity observed by in
vitro tests is in sharp contrast with the increased
associated thrombotic risk [1--4].
The generation of thrombin is the final common
path of the blood coagulation process and the se-
quence of events leading to activation and inhibition
processes has been referred to as the initiation,ed.
V. Regnault et al.540propagation and termination phases [5]. To ensure
reproducible results with standard clotting assays,
platelet-poor plasma (PPP) and either extensive
contact activation or a large excess of tissue factor
are traditionally used. Such strong triggers must be
deemed physiologically irrelevant. Moreover, clot-
ting, the end-point of these assays, coincides with
the onset of the thrombin burst (propagation
phase), a moment at which >95% of thrombin is still
to be generated [5,6]. Indeed, during recent years
the need for a general function test that reflects the
complexity of thrombin formation and inhibition has
been emphasized [7,8]. Several such tests have
been proposed, some using clot formation and
changes in the mechanical properties of the clot,
such as the thromboelastography [9], others based
on measuring thrombin generation.
Thrombin generation has been known for a
long time to be a valid physiological function test
[10,11]. The technique was revived in the 1980s
[6] and is now being increasingly utilized in a
number of different forms [12--16]. Its widespread
application has been hampered by the fact that
in its classical form it requires about one man-
hour of skilled laboratory work to obtain a curve.
The Calibrated Automated Thrombogram (CAT),
using a fluorogenic thrombin substrate and con-
tinuous comparison to a simultaneously run cali-
brator [17] relieves this limitation. CAT also
allows measurement in platelet-rich plasma
(PRP) [18].
The CAT methodology is sensitive to hyperco-
agulability and bleeding disorders [19,20]. We
have previously reported that the CAT methodol-
ogy can be conveniently implemented in clinical
research and that, in some instances, frozen-
thawed PRP, which allows the design of large
clinical studies with a core laboratory, can be
used to assess the effect of the protein C system
and known risk factors for thrombosis [21]. In LA-
patients, we demonstrated activated protein C
(APC) resistance despite the occurrence of long
initiation phases [22]. This paper will present
typical examples of phenotypic assessment of
the haemostatic system in inherited or acquired
prothrombotic disorders with focus on antiphos-
pholipid antibodies.Materials and methods
Reagents
Bovine serum albumin (BSA) and all chemicals were
from Sigma (St. Louis, MO, USA). Recombinant
human tissue factor was either a kind gift fromDade Behring (Marburg, Germany) or the commer-
cially available reagent Innovin from Dade Behring.
The fluorogenic substrate of thrombin, Z-Gly-Gly-
Arg-AMC, was from Bachem (Bubendorf, Switzer-
land) and the calibrator with a constant, known,
thrombin-like activity from Synapse (Maastricht,
The Netherlands). Soluble recombinant human
thrombomodulin (TM) was kindly provided by Asahi
(Japan) and APC was prepared in-house as previ-
ously described [23].
Blood and plasma
At venipuncture, blood was either drawn by vacu-
um into VacutainerR tubes (Becton Dickinson) or by
gentle suction into MonovetteR (Sarstedt) syringes,
1/10 volume of 0.129 or 0.106 M sodium citrate,
respectively. It was centrifuged at 194 g for 10
min at room temperature to obtain PRP and twice
at 2500 g for 10 min at room temperature to
obtain PPP. Platelets were counted using a Micros
60 ABX model (Montpellier, France) and adjusted to
150 109 platelets/L with autologous PPP. PRP was
used within 90 min after venipuncture unless oth-
erwise stated.
Calibrated automated thrombin activity
measurement
Thrombography was performed at 37 jC according
to Hemker et al. [12,19] in a microtiter plate
fluorometer (Fluoroskan Ascent, ThermoLabsys-
tems, Helinski, Finland) using the dedicated soft-
ware program (ThrombinoscopeR, Synapse), as
previously reported [21].
Briefly, coagulation was triggered by recalcifica-
tion in the presence of 0.5 pM recombinant human
tissue factor. Experiments were carried out in the
absence or in the presence of APC or TM at various
concentrations. The molar amount of thrombin
present in clotting plasma was calculated from
the signal of wells in which thrombin was generated
and the calibration signal [19]. The total amount of
thrombin activity (known as the endogenous throm-
bin potential---ETP) was assessed as the area under
the curve.Results
Most results are basically given as phenotypic
patterns: superimposed tracings of thrombin ac-
tivity as a function of time with PRP. Five con-
centrations of APC ranging from 0 to 65 nM
(corresponding to the activation of 100% of plas-
Figure 2 Effect of time before centrifugation of blood
and PRP storage on thrombin activity. PRP preparation
was initiated either 30 min (circles) or 120 min (squares)
after blood withdrawal; two recordings of thrombin
activity were started at 60 and 150 min after the onset
of PRP preparation, and are linked with short dashed and
dotted lines, respectively. Data obtained for six healthy
individuals in the absence or presence of 25 nM APC are
presented.
Phenotyping the haemostatic system by thrombography 541ma protein C) were studied. However, with the
exception of patients with antiphospholipid anti-
bodies (aPL), and for clarity’s sake, only results
obtained with 25 nM APC are presented. This
concentration was chosen assuming a similar cir-
culating level of APC in human plasma as those
reached in baboons infused with thrombin [24]
and it induces f 70% inhibition of ETP with
normal PRP [21].
Effect of preanalytical conditions and
storage
To evaluate the influence of preanalytical condi-
tions on thrombin activity in the absence or in
presence of the protein C system, we compared
the effect of vacuum during the drawing of blood
and of the time before centrifugation. It is seen in
Fig. 1 that using vacuum can lead to platelet
activation and decrease in APC sensitivity. These
changes are seen shortly after blood collection and
centrifugation and show significant variability be-
tween donors (Fig. 2).
Examples of typical inherited or acquired
hypercoagulability disorders
A typical phenotype of a control healthy subject
is shown on the left for each of the following
examples.
Fig. 3 shows a typical profile of inherited
antithrombin (AT) deficiency (plasma level: 62
U/dL). As expected, the most conspicuous differ-
ences lie in the peak of thrombin with a higher
value than normal and the termination phase with
a slower decay of thrombin activity than with the
control. As illustrated in the insets, the thrombinFigure 1 Effect of blood collection on thrombin activity. T
blood collection into Vacutainer (gray lines) or Monovette (bla
25 nM APC.potential is high when AT is deficient. APC re-
sponse (a 43% decrease in ETP with 25 nM APC)
falls within our control range obtained with 20
healthy individuals (median inhibition of ETP by
APC: 66%; range 43--77%).
A typical profile of inherited protein C deficien-
cy (plasma level: 50 U/dL) is shown in Fig. 4:
normal pattern of the effect of exogenous APC but
hardly any effect of added TM. The concentration
in TM was chosen in accordance with earlier
preliminary data showing a similar f 70% de-
crease in ETP with 25 nM APC or with 10 nM TM
[21]. Although the ETP is within the normal rangehrombograms observed with PRP prepared 30 min after
ck lines) tubes in the absence (left) or presence (right) of
Figure 3 Typical phenotype of inherited antithrombin deficiency. Left: control; right: patient with AT deficiency (AT
plasma level: 62 U/dL). Results are means of triplicate in the absence (black) or presence (gray) of 25 nM APC.
V. Regnault et al.542in the absence of APC, the defect in protein C
leads to elevated values when the endogenous
APC system is triggered.
Typical phenotypes of patients with aPL are
shown in Fig. 5. We previously reported prolonged
initiation phases of thrombin generation in LA-
patients together with a marked inability for APC
to diminish thrombin activity [22]. In fact, throm-
bograms of patients B, C and D (Fig. 5) are repre-
sentative of the three types of profile that we
observed with 30 aPL patients (data to be pub-
lished). Type 1: similar to the control (B); type 2:
decreased APC sensitivity (C) and type 3: almost no
inhibitory effect of added APC on ETP while it did
prolong the lag-phase (D). These effects are best
rendered by the ETP of the uninhibited sample
(1696, 1628, 1334 and 1253 nM.min for the control,
patients B, C and D, respectively) and the concen-
tration of APC that would give 50% inhibition---IC50-Figure 4 Typical phenotype of inherited protein C deficien
(protein C plasma level: 50 U/dL). Results are means of triplic
gray) or 25 nM APC (light gray).APC (15.3, 12.5, 36.8 and >65 nM for the control,
patients B, C and D, respectively). Even though the
IC50 concentration in APC is not reached with the
APC concentrations used for patient D, we did not
want to increase APC concentrations beyond phys-
iological levels.Discussion
Calibrated automated thrombography has been
proposed to identify hypercoagulability [17]. We
confirm the potential utility of such an integrative
assay for evaluating the haemostatic phenotype of
an individual, especially because the function of
the protein C system can be easily probed by adding
either exogenous APC or TM that, when thrombin is
formed, activates endogenous protein C.cy. Left: control; right: patient with protein C deficiency
ate in the absence (black) or presence of 10 nM TM (dark
Figure 5 Typical phenotypes of aPL patients. Panel A: control; panels B to D: three typical aPL patients. Added APC
concentrations: 0, 6.7, 13.9, 25 and 65 nM. Right panel: the inhibition of thrombin potential by APC was illustrated for
the matched control (black) and for patients B (dark gray), C (gray) and D (light gray). ETP values (nM.min): (A) 1696;
(B) 1628; (C) 1334; (D) 1253. IC50-APC values (nM): (A) 15.3; (B) 12.5; (C) 36.8; (D) >65.
Phenotyping the haemostatic system by thrombography 543Ideally carefully prepared fresh PRP should be
used to avoid artifacts due to accidental platelet
activation or to platelet aging. Our findings confirm
that the conditions of venesection are important in
particular with respect to PRP stability on the one
hand and APC sensitivity on the other hand. It is
interesting to note that storage of total blood
collected with minimal suction and subsequently
prepared PRP at room temperature for more than
180 min had no effect on the thrombogram (Fig. 2).
We nevertheless do not recommend this procedure
because (i) there are large individual variations in
behaviour, possibly also dependent upon the use of
medication and (ii) we have seen diminution of the
sensitivity of the platelet to antagonists of platelet
receptors.
Although for LA-patients the initiation phase is
prolonged by ‘‘definition’’ (otherwise there would
be no anticoagulant action), the maximal rate of
thrombin generation and the thrombin potential
value are often within the normal range.
Our data indicate that well-established condi-
tions associated with a persistent thrombotic risk
show a gain of function phenotype, i.e. increased
thrombin potential in the absence and/or in the
presence of added APC or TM. The thrombin poten-
tial in the absence of APC is not necessarily signif-icantly abnormal for patients with inherited protein
C deficiency or for patients with APL. Thus, the
amount of thrombin generated with an activated
protein C system could be more predictive of
thrombotic risk than when only tissue factor is
added.
A parameter directly related to the endogenous
thrombin potential is the level of the a2-macro-
globulin-thrombin complex in (defibrinated) ‘‘plas-
ma’’ after thrombin generation is over. An APC
sensitivity ratio (APCsr) can be calculated from
such levels obtained in the presence and in the
absence of APC. An association between APCsr and
the use of oral contraceptives as well as with factor
V G1691A polymorphism has been established but
conclusions are controversial regarding the associ-
ation of APCsr with venous thromboembolism
[25,26].
APCsr vary with the concentration in APC and
the choice of a concentration remains arbitrary. A
peak circulating APC level of 23 nM was reported
in baboons (concentrations in protein C and pro-
thrombin in the normal human range) infused with
thrombin [24] but the variability in the extent of
protein C-to-APC conversion in vivo is unknown
and a ‘‘physiological’’ concentration cannot be
established.
V. Regnault et al.544We therefore opted to characterize the individ-
ual patients by two parameters, the uninhibited
ETP and the concentration in APC that gives half
maximum inhibition of the thrombin potential
(IC50-APC). We can speculate that there exists a
value of the ETP, in the presence of a given amount
of APC, that best represents the in vivo situation
and therefore in itself is the indicator of the
thrombotic risk. As we do not know what that
amount might be we prefer to characterize the
situation by the uninhibited ETP on the one hand
and the IC50-APC on the other as a measure of the
APC-sensitivity.
Thrombin generation has been reported to be
associated with a number of features of each
coagulation factor [20,27]. A blood composition-
defined propensity for any given individual to
respond with a characteristic amount of thrombin
work for a given appropriate tissue factor stimulus
has been evidenced [16,19,21]. Thus, the thrombin
potential in the presence of APC appears to inte-
grate most variables with, however, the above-
mentioned limitation on the choice of APC con-
centration. Mutatis mutandis, the same holds for
the addition of soluble TM. Only carefully designed
and conducted clinical studies can tell us whether
our hypotheses are correct [28]. Thus a study
program has been initiated. First the study of a
sample of the general population will provide
reference values. Second, a case-control study will
estimate the risk of occurrence of first thrombotic
event associated with hypercoagulabil ity
evidenced by thrombography in patients with an
antiphospholipid syndrome or a systemic lupus
erythematosus. Third, since a case-control design
cannot sufficiently consider time-dependent
effects both from the exposure variable and the
potential confounders it will be followed by a
prospective cohort study.Acknowledgements
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